Payer Mix Analysis: Autoimmune Encephalitis (AIE) and Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
UCB recently engaged Milliman to estimate the distribution of patients with autoimmune encephalitis (AIE) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD). AIE is a group of autoimmune disorders that affect the brain and cause inflammation of the brain. MOG-AD is a disorder caused by inflammatory attacks of the central nervous system. Milliman conducted a claims-based analysis for AIE, as well as a literature-based analysis for AIE and MOG-AD. The following payer channels are included in the analysis:
- Medicare Fee-for-Service (FFS)
- Medicare Advantage
- Commercial
- Medicaid (FFS and managed care)
This report was commissioned by UCB, Inc.
About the Author(s)
Payer Mix Analysis: Autoimmune Encephalitis (AIE) and Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
Medicare FFS and Advantage show the highest rates of AIE prevalence of at least 8 per 100,000, more than double than that in the commercial channel.